Home › Research › Brain scans and imaging
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls
Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K et al.. Neurology, 2009-09-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective In Alzheimer disease (AD), the accumulation pattern of beta-amyloid over time and its relationship with dementia severity are unclear. We investigated the brain uptake of the amyloid ligand (11)C-labeled Pittsburgh compound B ([(11)C]PIB) and volumetric brain changes over a 2-year follow-up in patients with AD and in aged healthy controls. Methods Fourteen patients with AD (mean age 72 years, SD 6.6) and 13 healthy controls (mean age 68 years, SD 5.4) were examined at baseline and after 2 years (patients with AD: mean 2.0 years, SD 0.2; controls: mean 2.1 years, SD 0.6) with [(11)C]PIB PET, MRI, and neuropsychological assessments. [(11)C]PIB uptake was analyzed with a voxel-based statistical method (SPM), and quantitative data were obtained with automated region-of-interest analysis. MRI data were analyzed with voxel-wise tensor-based morphometry. Results The [(11)C]PIB uptake of the patients with AD did not increase significantly during follow-up when compared with that of the controls. MRI showed progressive brain volume change in the patients with AD, e.g., in the hippocampal region, temporal cortex, and precuneus (p Conclusions The results suggest no (or only little) increase in (11)C-labeled Pittsburgh compound B ([(11)C]PIB) uptake during 2 years of Alzheimer disease progression, despite advancing brain atrophy and declining cognitive performance. Nevertheless, changes in [(11)C]PIB uptake during a longer follow-up cannot be excluded. High cortical [(11)C]PIB uptake may predict ongoing brain atrophy in cognitively normal individuals.
What this study adds
Evidence grade: Low
In patients with Alzheimer's disease, Pittsburgh compound B uptake did not increase significantly over two years compared with controls, despite progressive brain volume loss and declining cognitive performance. This suggests no or only little increase in amyloid tracer uptake during Alzheimer's disease progression over this period.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Scheinin, N. M., Aalto, S., Koikkalainen, J., Lötjönen, J., Karrasch, M., Kemppainen, N., et al. (2009). Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. https://doi.org/10.1212/wnl.0b013e3181bacf1b
Vancouver
Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009. doi:10.1212/wnl.0b013e3181bacf1b. PMID: 19726751.
BibTeX
@article{scheinin2009-19726751,
author = {Scheinin, N. M. and Aalto, S. and Koikkalainen, J. and Lötjönen, J. and Karrasch, M. and Kemppainen, N. and Viitanen, M. and Någren, K. and others},
title = {{Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls}},
journal = {Neurology},
year = {2009},
doi = {10.1212/wnl.0b013e3181bacf1b},
pmid = {19726751},
url = {https://doi.org/10.1212/wnl.0b013e3181bacf1b}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The [(11)C]PIB uptake of the patients with AD did not increase significantly during follow-up when compared with that of the controls.
- MRI showed progressive brain volume change in the patients with AD, e.g., in the hippocampal region, temporal cortex, and precuneus (p < 0.05).
Why it matters
In patients with Alzheimer's disease, Pittsburgh compound B uptake did not increase significantly over two years compared with controls, despite progressive brain volume loss and declining cognitive performance. This suggests no or only little increase in amyloid tracer uptake during Alzheimer's disease progression over this period.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 129 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.8 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 4 / 6 | Cited 12.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 25 other studies in this library |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Juha O. Rinne: h-index 99 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Karolinska Institutet: institution h-index 1,477 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19726751) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain scans and imaging from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.